Paper Details

  1. Home
  2. Paper Details

Cardiometabolic profile, clinical features, quality of life and treatment outcomes in patients with moderate-to-severe psoriasis and psoriatic arthritis.

Author: BoggsRobert, HusniM Elaine, KoenigAndrew S, NoppakunNopadon, PuigLuis, RobertsonDeborah, StrohalRobert, SzumskiAnnette, TsaiTsen-Fang, YangShiyi

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study found that people with moderate to severe psoriasis, with or without psoriatic arthritis (PsA), had a high prevalence of cardiovascular risk factors like high blood pressure and diabetes. Etanercept treatment significantly improved psoriasis symptoms and quality of life in both groups, with those who also had PsA showing greater improvements in quality of life. The study highlights the importance of monitoring cardiovascular health in people with psoriasis and the benefits of etanercept for improving skin symptoms and quality of life.
Paper Details　
Original Abstract of the Article :
Cardiometabolic, clinical and quality-of-life (QoL) measures were assessed before and after etanercept treatment in patients who had moderate-to-severe plaque psoriasis with and without psoriatic arthritis (PsA) in the PRISTINE trial. Adult patients were randomized to receive etanercept 50 mg once w...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.3109/09546634.2013.860209

データ提供：米国国立医学図書館（NLM）

Cardiometabolic Profile and Treatment Outcomes in Moderate-to-Severe Psoriasis and Psoriatic Arthritis

This study focuses on [psoriasis] and [psoriatic arthritis (PsA)], chronic inflammatory conditions that can significantly impact quality of life. The study investigates the [cardiometabolic profile] and [treatment outcomes] of patients with moderate-to-severe plaque psoriasis with and without PsA, using [etanercept] as a treatment. The study found that cardiovascular comorbidities were common in patients with psoriasis, highlighting the importance of monitoring cardiometabolic parameters in this population. The study also demonstrated significant improvements in psoriasis severity and quality of life with etanercept therapy, suggesting its effectiveness in managing these conditions.

Managing Psoriasis and PsA: Addressing Cardiometabolic Risks and Improving Quality of Life

This research underscores the importance of addressing the cardiometabolic risks associated with psoriasis and PsA. It highlights the need for comprehensive management strategies that include monitoring cardiometabolic parameters and promoting healthy lifestyle habits. The study's findings also demonstrate the effectiveness of etanercept therapy in improving psoriasis severity and quality of life, offering a valuable treatment option for patients with these conditions.

Promoting Whole-Person Care for Psoriasis and PsA Patients

This research emphasizes the importance of a holistic approach to managing psoriasis and PsA. It underscores the need for comprehensive care that addresses not only skin symptoms but also cardiometabolic risks and quality of life. By adopting a whole-person approach, healthcare providers can optimize patient outcomes and improve the overall well-being of individuals with psoriasis and PsA.

Dr.Camel's Conclusion

This study provides valuable insights into the management of psoriasis and psoriatic arthritis, highlighting the importance of addressing cardiometabolic risks and improving quality of life. The study's findings suggest that etanercept therapy can be an effective treatment option for these conditions, offering hope for patients seeking relief from their symptoms. As Dr. Camel, I believe that this research underscores the importance of a comprehensive and personalized approach to managing these chronic inflammatory conditions.

Date :
  1. Date Completed 2015-07-16
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

24283931

DOI: Digital Object Identifier

10.3109/09546634.2013.860209

Related Literature

Article Analysis
・Effective treatment of psoriatic arthritis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.